aTyr Pharma (LIFE) | Financial Analysis & Statements
aTyr Pharma Inc Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
110.1M
Gross Profit
108.0M
98.13%
Operating Income
24.5M
22.23%
Net Income
24.6M
22.31%
EPS (Diluted)
$0.39
Balance Sheet Metrics
Total Assets
515.3M
Total Liabilities
539.5M
Shareholders Equity
-24.1M
Cash Flow Metrics
Operating Cash Flow
9.7M
Free Cash Flow
1.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
aTyr Pharma Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 387.6M | 254.9M | 159.8M | 10.4M | 0 |
| Cost of Goods Sold | 6.7M | 6.5M | 5.9M | - | - |
| Gross Profit | 380.9M | 248.4M | 153.9M | - | - |
| Gross Margin % | 98.3% | 97.4% | 96.3% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | - | - | - | 42.8M | 23.3M |
| Selling, General & Administrative | 269.0M | 171.1M | 128.8M | 14.0M | 10.8M |
| Other Operating Expenses | 33.6M | 23.1M | 22.3M | - | - |
| Total Operating Expenses | 302.6M | 194.2M | 151.0M | 56.8M | 34.0M |
| Operating Income | 72.9M | 48.7M | -2.9M | -46.4M | -34.0M |
| Operating Margin % | 18.8% | 19.1% | -1.8% | -446.8% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 5.8M | 5.6M | 5.8M | - | - |
| Interest Expense | 3.2M | 595.0K | 723.0K | - | - |
| Other Non-Operating Income | 161.0K | 185.0K | 117.0K | 1.1M | 238.0K |
| Pre-tax Income | 75.7M | 53.9M | 2.3M | -45.3M | -33.8M |
| Income Tax | 4.6M | 5.1M | 586.0K | - | - |
| Effective Tax Rate % | 6.1% | 9.5% | 25.8% | 0.0% | 0.0% |
| Net Income | 71.2M | 48.8M | 1.7M | -45.3M | -33.8M |
| Net Margin % | 18.4% | 19.2% | 1.1% | -436.6% | 0.0% |
| Key Metrics | |||||
| EBITDA | 85.2M | 60.0M | 8.7M | -44.7M | -32.7M |
| EPS (Basic) | - | $0.78 | $0.03 | $-1.60 | $-1.77 |
| EPS (Diluted) | - | $0.78 | $0.03 | $-1.60 | $-1.77 |
| Basic Shares Outstanding | - | 62558380 | 62558380 | 28419569 | 19080878 |
| Diluted Shares Outstanding | - | 62558380 | 62558380 | 28419569 | 19080878 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
aTyr Pharma Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 91.1M | 35.1M | 25.0M | 10.0M | 2.3M |
| Short-term Investments | 34.9M | 68.3M | 104.0M | 56.2M | 105.6M |
| Accounts Receivable | 65.3M | 45.4M | 17.7M | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 7.0M | 3.5M | 2.2M | 3.0M | 5.2M |
| Total Current Assets | 245.8M | 174.8M | 148.9M | 80.9M | 113.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.3M | 2.7M | 87.0K | 5.6M | 5.6M |
| Goodwill | 5.1M | 4.7M | 4.5M | - | - |
| Intangible Assets | 662.0K | 221.0K | 30.0K | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 224.8M | 173.7M | 119.4M | 3.4M | 158.0K |
| Total Non-Current Assets | 269.5M | 221.1M | 130.8M | 14.9M | 2.0M |
| Total Assets | 515.3M | 395.9M | 279.7M | 95.8M | 115.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 66.8M | 33.7M | 13.1M | 3.1M | 1.0M |
| Short-term Debt | 1.1M | 753.0K | 549.0K | 894.0K | 980.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 50.0K | 66.0K | 22.0K | - | - |
| Total Current Liabilities | 113.2M | 67.6M | 27.1M | 13.9M | 6.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.2M | 1.9M | 249.0K | 10.6M | 398.0K |
| Deferred Tax Liabilities | 8.5M | 3.9M | 0 | - | - |
| Other Non-Current Liabilities | 12.5M | 25.7M | 7.5M | - | - |
| Total Non-Current Liabilities | 426.3M | 435.4M | 411.7M | 10.6M | 398.0K |
| Total Liabilities | 539.5M | 503.0M | 438.8M | 24.5M | 6.4M |
| Equity | |||||
| Common Stock | 2.0K | 2.0K | 2.0K | 29.0K | 28.0K |
| Retained Earnings | -102.5M | -173.7M | -222.5M | -417.6M | -372.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -24.1M | -107.2M | -159.2M | 71.3M | 109.1M |
| Key Metrics | |||||
| Total Debt | 2.4M | 2.6M | 798.0K | 11.5M | 1.4M |
| Working Capital | 132.6M | 107.2M | 121.8M | 67.0M | 107.6M |
Balance Sheet Composition
aTyr Pharma Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 71.2M | 48.8M | 1.7M | -45.3M | -33.8M |
| Depreciation & Amortization | 6.3M | 5.5M | 5.7M | 1.7M | 1.3M |
| Stock-Based Compensation | 10.6M | 3.2M | 3.6M | 2.2M | 1.6M |
| Working Capital Changes | -55.6M | -53.0M | -46.9M | -9.8M | 743.0K |
| Operating Cash Flow | 39.0M | 5.9M | -38.8M | -51.3M | -29.8M |
| Investing Activities | |||||
| Capital Expenditures | -1.5M | -776.0K | -323.0K | -1.5M | -142.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -66.7M | -154.7M | -154.2M | -42.1M | -126.5M |
| Investment Sales | 104.9M | 158.4M | 149.9M | 90.8M | 35.1M |
| Investing Cash Flow | 36.7M | 2.9M | -4.6M | 47.2M | -91.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | -66.0K | 0 |
| Financing Cash Flow | -13.1M | 21.6M | -2.0M | 5.4M | 110.0M |
| Free Cash Flow | 29.9M | -15.5M | -42.0M | -43.5M | -33.3M |
| Net Change in Cash | 62.5M | 30.5M | -45.3M | 1.3M | -11.4M |
Cash Flow Trend
aTyr Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.35
Forward P/E
8.46
Price to Book
-42.41
Price to Sales
2.65
PEG Ratio
8.46
Profitability Ratios
Profit Margin
18.36%
Operating Margin
22.23%
Return on Equity
21.03%
Return on Assets
10.00%
Financial Health
Current Ratio
2.17
Debt to Equity
0.62
Per Share Data
EPS (TTM)
$1.14
Book Value per Share
$-1.45
Revenue per Share
$23.51
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| LIFE | 1.0B | 14.35 | -42.41 | 21.03% | 18.36% | 0.62 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






